Analysis of yearly variations in drug expenditure for one patient using data warehouse in a hospital

Journal of Medical Systems

Volumn 31, Issue 1, 2007, Pages 17-24

  Chen, Yufeng ^a   Matsumura, Yasushi ^a   Nakagawa, Katsuhiko ^a   Ji, Shanmei ^a   Nakano, Hirohiko ^a   Teratani, Tadamasa ^a   Zhang, Qiyan ^a   Mineno, Takahiro ^a   Takeda, Hiroshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Data warehouse; Drug expenditure; Drug price; Medical cost; Prescription

Indexed keywords

ARTICLE; DATA ANALYSIS; DATA BASE; DRUG COST; HOSPITAL; PRESCRIPTION;

ANTIHYPERTENSIVE AGENTS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DRUG COSTS; DRUG UTILIZATION; HEALTH EXPENDITURES; HOSPITAL INFORMATION SYSTEMS; HOSPITALS; HUMANS; JAPAN; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; PROGRAMMING LANGUAGES; TIME FACTORS;

EID: 33845948582     PISSN: 01485598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10916-006-9039-7     Document Type: Article

References (17)

1. Belien, P., Healthcare reform in Europe. Pharmacoeconomics, 10(Suppl. 2):94-9, 1996.
2. Ministry of Health, Labor and Welfare, Gyousei, Tokyo, White Book of Ministry of Health, Labor and Welfare, Medical Cost of Whole Nation, p. 527, 2005.
3. Ikegami, N., Drummond, M., Fukuhara, S. Why has the use of health economic evaluation in Japan lagged behind that in other developed countries? Pharmacoeconomics, 20(Suppl. 2):1-7, 2002.
4. Noyce, P. R., Huttin, C., Atella, V., et al. The cost of prescription medicines to patients. Health Policy Jun.; 52(2):129-45, 2000.
5. Shah, N. D., Hoffman, J. M., Vermeulen, L. C., et al. Projecting future drug expenditures-2003. Am J Health Syst Pharm. Jan 15; 60(2): 137-49, 2003.
6. Sherman, D., for the Barents Group LLC. Factors affection the growth of prescription drug expenditures. Washington, DC: The National Institute for Health Care Management Research and Educational Foundation, Jul 9, 1999.
7. Dubois, R. W., Chawla, A. J., Neslusan, C. A., et al. Explaining drug spending trends: Does perception match reality? Health Affairs Mar-Apr. 19(2):231-9, 2000.
8. Ministry of Health, Labor and Welfare, Gyousei, Tokyo, White Book of Ministry of Health, Labor and Welfare, Medical Cost of Whole Nation, p 440, 1999.
9. Tokita, T., Chino, T., Kitaki, H., et al. The present and future national medical expenditure in Japan. Tokyo, Japan: Economic Research Institute, Economic Planning Agency, 1997.
10. Anderson, G. F., Poullier, J. P.. Health spending, access, and outcomes: Trends in industrialized countries. Health Aff (Millwood). May-Jun.;18(3):178-92, 1999.
11. Anderson, G. F., Hussey, P. S. Population aging: A comparison among industrialized countries. Health Aff (Millwood). May-Jun.;19(3):191-203, 2000.
12. Kawabuchi, K.Y., About the price-of-medicine policy in Japan. Gekkann Hodannrenn. 9(626):1999.
13. Tachikawa, K., Nakagawa, K., Magnitude of Co-payment increase impact to design pharmacotherapy for hypertensive patients from the interview report about economical burden issues in both physicians and patients. Jpn Pharmacol Ther. 28(9), 2000.
14. Hisashige A. Medicine therapy and cost-effectiveness for the prevention of apoplexy. Prog Med. 21:1295-1299, 2001.
15. Ruilope, L., Human pharmacokinetic/pharmacodynamic profile of irbesartan: A new potent angiotensin II receptor antagonist. J Hypertens. 15(suppl 7):s15-s20, 1997.
16. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 157:2413-2446, 1997.
17. Guidelines Subcommittee. 1999 world health organization-international society of hypertension guidelines for the management of hypertension. J Hypertens. 17:151-83, 1999.